Background: NORSTENT trial randomized 9,013 patients to percutaneous coronary intervention with drug-eluting stents (DES) or bare-metal stents (BMS) with a 5-year follow-up. Among the patients, 5,512 had measured either fasting glucose level or percent glycated hemoglobin (HbA1c) at the index procedure. That cohort constitutes the present study population analyzing mortality and evaluating treatment heterogeneity of randomized stent in diabetic versus nondiabetic subgroups. Results: The cohort consisted of 4,174 (75.7%) patients without diabetes, 716 (13.0%) with known diabetes, and 622 (11.3%) with no diabetes in history but elevated fasting glucose level >7.0 mmol/L or HbA1c >6.5% and therefore defined as new diabetes. Patients with known diabetes had a significantly increased all-cause (hazard ratio [HR] 1.99, 95% CI 1.51–2.62, p < 0.001), cardiac (subhazard ratio [SHR] 2.47, 95% CI 1.55–3.93, p < 0.001), and noncardiac (SHR 1.74, 95% CI 1.23–2.44, p = 0.002) mortality after adjustment for baseline variables. In the follow-up of 5 years, patients with new diabetes, however, had a marginally increased all-cause (HR 1.40, 95% CI 1.01–1.93, p = 0.043) and significantly increased noncardiac mortality (SHR 1.52, 95% CI 1.06–2.20, p = 0.025), but no increase in cardiac mortality (SHR 1.06, 95% CI 0.53–2.12, p = 0.86) after the same adjustment. The majority of the mortality was cardiac in the first 1–2 years after intervention; thereafter, noncardiac mortality dominated. However, the time period for when noncardiac mortality became the dominating cause varied considerably and significantly between the groups. There was no heterogeneity in mortality in response to randomized stent between diabetics and nondiabetics. Conclusion: Known diabetes has increased cardiac and noncardiac mortality in contrast to new diabetes which is only associated with increased noncardiac mortality during the 5-year follow-up. Diabetic and nondiabetic patients have the same response to the treatment with BMS or DES.

1.
Huxley
R
,
Barzi
F
,
Woodward
M
.
Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies
.
BMJ
.
2006 Jan 14
;
332
(
7533
):
73
8
. .
2.
Norhammar
A
,
Lindbäck
J
,
Rydén
L
,
Wallentin
L
,
Stenestrand
U
.
Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission
.
Heart
.
2007 Dec
;
93
(
12
):
1577
83
. .
3.
Preis
SR
,
Hwang
SJ
,
Coady
S
,
Pencina
MJ
,
D’Agostino
RB
,
Savage
PJ
, et al.
Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005
.
Circulation
.
2009 Apr 7
;
119
(
13
):
1728
35
. .
4.
Lima
EG
,
Hueb
W
,
Garcia
RM
,
Pereira
AC
,
Soares
PR
,
Favarato
D
, et al.
Impact of diabetes on 10-year outcomes of patients with multivessel coronary artery disease in the Medicine, Angioplasty, or Surgery Study II (MASS II) trial
.
Am Heart J
.
2013 Aug
;
166
(
2
):
250
7
. .
5.
Alabas
OA
,
Hall
M
,
Dondo
TB
,
Rutherford
MJ
,
Timmis
AD
,
Batin
PD
, et al.
Long-term excess mortality associated with diabetes following acute myocardial infarction: a population-based cohort study
.
J Epidemiol Community Health
.
2017 Jan
;
71
(
1
):
25
32
. .
6.
Mølstad
P
,
Rødevand
O
.
Survival in type 1 and type 2 diabetes in a population referred for invasive evaluation of coronary disease
.
Cardiology
.
2018
;
139
(
1
):
43
52
.
7.
Bonaa
KH
,
Mannsverk
J
,
Wiseth
R
,
Aaberge
L
,
Myreng
Y
,
Nygard
O
, et al.
Drug-eluting or bare-metal stents for coronary artery disease
.
N Engl J Med
.
2016 Sep 29
;
375
(
13
):
1242
52
.
8.
Mølstad
P
,
Nordrehaug
JE
,
Steigen
T
,
Giil
LM
,
Wilsgaard
T
,
Wiseth
R
, et al.
The effect of drug-eluting stents on target lesion revascularization in native coronary arteries: results from the NORSTENT randomized study
.
Cardiology
.
2020
;
145
(
6
):
333
41
. .
9.
Shrier
I
,
Platt
RW
.
Reducing bias through directed acyclic graphs
.
BMC Med Res Methodol
.
2008 Oct 30
;
8
:
70
. .
10.
Textor
J
,
van der Zander
B
,
Gilthorpe
MS
,
Liśkiewicz
M
,
Ellison
GT
.
Robust causal inference using directed acyclic graphs: the R package “dagitty”
.
Int J Epidemiol
.
2017
;
45
(
6
):
1887
94
.
11.
Mølstad
P
,
Nustad
M
.
Acute myocardial infarction in diabetic patients
.
Acta Med Scand
.
1987
;
222
(
5
):
433
7
.
12.
Baena-Díez
JM
,
Peñafiel
J
,
Subirana
I
,
Ramos
R
,
Elosua
R
,
Marín-Ibañez
A
, et al.
Risk of cause-specific death in individuals with diabetes: a competing risks analysis
.
Diabetes Care
.
2016 Nov
;
39
(
11
):
1987
95
. .
13.
Yu
OH
,
Suissa
S
.
Identifying causes for excess mortality in patients with diabetes: closer but not there yet
.
Diabetes Care
.
2016 Nov
;
39
(
11
):
1851
3
. .
14.
Wang
Q
,
Liu
H
,
Ding
J
.
Cardiac versus non-cardiac related mortality following percutaneous coronary intervention in patients with insulin-treated type 2 diabetes mellitus: a meta-analysis
.
Diabetes Ther
.
2018 Jun
;
9
(
3
):
1335
45
. .
15.
Giovannucci
E
,
Harlan
DM
,
Archer
MC
,
Bergenstal
RM
,
Gapstur
SM
,
Habel
LA
, et al.
Diabetes and cancer: a consensus report
.
Diabetes Care
.
2010 Jul
;
33
(
7
):
1674
85
. .
16.
Lin
CM
,
Huang
HL
,
Chu
FY
,
Fan
HC
,
Chen
HA
,
Chu
DM
, et al.
Association between gastroenterological malignancy and diabetes mellitus and anti-diabetic therapy: a nationwide, population-based cohort study
.
PLoS One
.
2015
;
10
(
5
):
e0125421
. .
17.
Wu
BU
,
Butler
RK
,
Lustigova
E
,
Lawrence
JM
,
Chen
W
.
Association of glycated hemoglobin levels with risk of pancreatic cancer
.
JAMA Netw Open
.
2020
;
3
(
6
):
e204945
.
18.
Tu
JV
,
Bowen
J
,
Chiu
M
,
Ko
DT
,
Austin
PC
,
He
Y
, et al.
Effectiveness and safety of drug-eluting stents in Ontario
.
N Engl J Med
.
2007 Oct 4
;
357
(
14
):
1393
402
. .
19.
Cassese
S
,
Byrne
RA
,
Tada
T
,
Pinieck
S
,
Joner
M
,
Ibrahim
T
, et al.
Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography
.
Heart
.
2014 Jan
;
100
(
2
):
153
9
. .
20.
Taniwaki
M
,
Stefanini
GG
,
Silber
S
,
Richardt
G
,
Vranckx
P
,
Serruys
PW
, et al.
4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A randomized comparison of a Zotarolimus-Eluting stent with an Everolimus-Eluting stent for percutaneous coronary intervention)
.
J Am Coll Cardiol
.
2014 Apr 29
;
63
(
16
):
1617
25
. .
21.
Rao Kondapally Seshasai
S
,
Kaptoge
S
,
Thompson
A
,
Di Angelantonio
E
,
Gao
P
,
Sarwar
N
, et al.
Diabetes mellitus, fasting glucose, and risk of cause-specific death
.
N Engl J Med
.
2011 Mar 3
;
364
(
9
):
829
41
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.